Research Article: CCDC as a Prognostic Biomarker Correlated with Tumor Progression and Immune Infiltration in Glioma
Abstract:
Gliomas originate from brain glial cells. It is the most common primary intracranial tumor, accounting for about % of malignant tumors in the central nervous system. Temozolomide combined with radiotherapy and chemotherapy is the standard treatment after surgery. However, the median survival time of patients is still not more than years. The discovery of functional lymphatic vessels within the dural sinuses unveils fresh evidence supporting active immune surveillance in the central nervous system (CNS). Novel therapeutic avenues for glioma treatment encompass immune checkpoint inhibitors (ICIs), viral therapy, CAR-T therapy, and vaccine treatment. However, the present immunotherapy options for glioma exhibit inadequate therapeutic efficacy due to the intricate immunosuppressive environment and systemic immunosuppression prevalent in gliomas. Hence, the quest for novel immune-related indicators and therapeutic targets remains pivotal in fostering advancements in glioma treatment.
Introduction:
Gliomas originate from brain glial cells. It is the most common primary intracranial tumor, accounting for about % of malignant tumors in the central nervous system. Temozolomide combined with radiotherapy and chemotherapy is the standard treatment after surgery. However, the median survival time of patients is still not more than years. The discovery of functional lymphatic vessels within the dural sinuses unveils fresh evidence supporting active immune surveillance in the central nervous system (CNS). Novel…
Read more